SynthesisEndocrinology, diabetes & metabolism2025
The Relationship Between Irritable Bowel Syndrome and Metabolic Syndrome: A Systematic Review and Meta-Analysis of 49,662 Individuals.
Synthesis in Endocrinology, diabetes & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Irritable Bowel Syndrome and Incident Hypertension: Epidemiologic and Genetic Insights.Biomedicines · 2026Article
- Tormentil Rhizome Ethanolic Extract and Its Gut Microbiota-Derived Metabolites: Modulation of Tight Junction Integrity and Anti-Inflammatory Potential in Caco-2 Cells.Journal of agricultural and food chemistry · 2026Article
- Is MASLD Not Just a Liver Disease? Bidirectional Gut-Liver Crosstalk as a Driver of Chronic Liver Disease.Life (Basel, Switzerland) · 2026Review
- Cardiometabolic Burden of Irritable Bowel Syndrome: A Case-Control Analysis of Metabolic Syndrome Clustering.Journal of epidemiology and global health · 2026Article
- Gut hormones in POTS and their relation to hemodynamic parameters and gastrointestinal symptoms.Scientific reports · 2026Article
- Article
- Masked hypertension in irritable bowel syndrome: A cause for concern?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Comparison of acupuncture, moxibustion, and pharmacotherapy in improving diarrhea-predominant irritable bowel syndrome.Frontiers in microbiology · 2025Article
- A set of downregulated pleiotropic genes are possible multi-omics biomarkers underlying the irritable bowel syndrome-non-alcoholic fatty liver disease comorbidity.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have shown mixed results regarding the association between irritable bowel syndrome (IBS) and metabolic syndrome (MS); This study aimed to assess the susceptibility of IBS patients to MS and its individual components.
methodsPubMed, Scopus, Embase, and Web of Science were searched on 1/1/2023. Eligible studies were screened, and data on study characteristics, IBS diagnostic criteria, and metabolic syndrome components were extracted. Data were analysed in RevMan 5.4, with results reported as relative risk (RR) or mean difference (MD) and 95% confidence intervals. Statistical significance was set at p < 0.05.
resultsIBS was associated with an increased risk of MS (RR = 2.05, 95% CI = 1.50-2.79, p < 0.00001), with a higher risk among IBS-D patients (RR = 3.09, 95% CI = 2.41-3.97, p < 0.00001). IBS patients showed increased HOMA-IR (MD = 0.21, 95% CI = 0.15-0.26, p < 0.00001), higher obesity risk (RR = 1.46, 95% CI = 1.10-1.93, p = 0.009), elevated BMI (MD = 1.51, 95% CI = 0.98-2.03, p-value < 0.00001), waist circumference (MD = 5.01, 95% CI = 1.29-8.72, p = 0.008), and an association with systolic hypertension (MD = -0.50, 95% CI = -0.60 to -0.40, p-value < 0.00001). IBS was also linked to higher LDL (MD = 5.98, 95% CI = 0.91-11.05, p = 0.02), total cholesterol (MD = 12.21, 95% CI = 6.23-18.18, p < 0.0001), and triglycerides (MD = 11.93, 95% CI = 11.55-12.31, p < 0.00001).
conclusionsThis analysis indicates a potential association between IBS and metabolic syndrome, including its components such as obesity, hypertension, and lipid profile abnormalities. However, significant heterogeneity among studies limits the generalisability of these findings. Clinicians should remain aware of the possible link and consider individualised preventive and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.